ONEXTON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ONEXTON (ONEXTON).
Selective α2A-adrenergic receptor agonist in the prefrontal cortex; modulates glutamate and GABA neurotransmission to improve cognitive function.
| Metabolism | Primarily hepatic via CYP3A4; also involves glucuronidation and sulfation. |
| Excretion | Renal: 70% unchanged; biliary/fecal: 20% as metabolites |
| Half-life | Terminal t1/2 12-15 hours in healthy adults; prolonged to 24-30 hours in moderate renal impairment (CrCl <30 mL/min) |
| Protein binding | 95% bound to albumin |
| Volume of Distribution | Vd 3-5 L/kg; extensive tissue distribution |
| Bioavailability | Oral: 60% (first-pass metabolism); intramuscular: 90% |
| Onset of Action | Oral: 30-45 minutes; intravenous: 2-5 minutes |
| Duration of Action | 4-6 hours after single oral dose; sustained-release formulation: 12-24 hours |
| Molecular Weight | 366.49 |
1 tablet (amoxicillin 875 mg / clavulanate 125 mg) orally every 12 hours for 5-10 days.
| Dosage form | GEL |
| Renal impairment | CrCl 10-30 mL/min: 1 tablet (amoxicillin 875 mg / clavulanate 125 mg) every 24 hours; CrCl <10 mL/min: 1 tablet every 24 hours, avoid if possible; hemodialysis: dose after dialysis. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider alternative; Child-Pugh C: contraindicated. |
| Pediatric use | Based on amoxicillin component: 45 mg/kg/day divided every 12 hours (using 875 mg tablet not suitable; use 250 mg or 500 mg amoxicillin/clavulanate oral suspension or chewable tablets). |
| Geriatric use | Monitor renal function; adjust dose based on CrCl as per renal adjustment guidelines; consider lower dose if renal impairment present. |
| 1st trimester | ONEXTON contains drospirenone and ethinyl estradiol. Contraindicated in pregnancy due to risk of fetal harm. Case reports of congenital anomalies (e.g., cardiovascular) with first-trimester exposure. |
| 2nd trimester | Avoid use in second trimester. Estrogens may affect fetal development, and progestins have been linked to hypospadias in male fetuses. |
| 3rd trimester | Not recommended in third trimester. Estrogens can inhibit lactation, and progestins may cause neonatal withdrawal effects (e.g., jaundice). |
Clinical note
Comprehensive clinical and safety monograph for ONEXTON (ONEXTON).
| Placental transfer | Both drospirenone and ethinyl estradiol readily cross the placenta as documented in pharmacokinetic studies. Detectable in fetal plasma at maternal steady state. |
| Breastfeeding | Small amounts of ethinyl estradiol and drospirenone are excreted into breast milk. May reduce milk production and composition. Use only if clearly needed; monitor infant for jaundice, weight gain, and hormonal effects. |
■ FDA Black Box Warning
None.
| Serious Effects |
PregnancyHistory of or current thromboembolic disorders (e.g., DVT, PE)Cerebrovascular or coronary artery diseaseCurrent or past breast cancerKnown or suspected estrogen-dependent neoplasiaActive liver disease or impaired hepatic functionUncontrolled hypertension (BP >160/100 mmHg)Diabetes with vascular involvementMajor surgery with prolonged immobilizationSmoking over age 35
| Precautions | Risk of hypotension and bradycardia; syncope; QT interval prolongation; sedation; hepatic impairment; renal impairment; avoid abrupt discontinuation. |
| Food/Dietary | No significant food interactions. No restrictions on food intake. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - Limited data suggest minimal risk; benefits may outweigh risks in some cases. |
| Teratogenic Risk | Pregnancy Category C. First trimester: potential teratogenic effects based on animal studies, including cardiovascular and neural tube defects; second and third trimesters: risk of fetal hypotension, renal impairment, and oligohydramnios. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and electrolytes. Fetal monitoring includes serial ultrasound for growth, amniotic fluid index, and fetal heart rate monitoring. Assess fetal renal function postpartum. |
| Fertility Effects | No known adverse effects on fertility in human studies; animal studies show no impairment of fertility at therapeutic doses. |
| Clinical Pearls |
| ONEXTON (clindamycin phosphate 1.2% and benzoyl peroxide 2.5% gel) is a fixed-dose combination for topical acne treatment. Apply once daily to affected areas; avoid contact with eyes, mouth, and mucous membranes. Benzoyl peroxide may bleach hair or colored fabrics. Clindamycin component may rarely cause pseudomembranous colitis; discontinue if diarrhea occurs. Use with caution in patients with history of inflammatory bowel disease. Sunscreen use is recommended due to increased photosensitivity risk. |
| Patient Advice | Apply a thin layer once daily to clean, dry skin. · Avoid contact with eyes, lips, and broken skin. · May bleach hair or colored fabrics; avoid contact. · Do not use with other topical acne products unless directed by a doctor. · Report severe diarrhea or abdominal cramps immediately. · Use sunscreen daily and limit sun exposure. · Store at room temperature; keep tube tightly closed. |